

In re Application of:
Dennis et al.
Application No.: 09/493,601
Filed: January 28, 2000
Page 2

PATENT
Attorney Docket No.: ST-UCSD3130
(formerly 041673-0301)

Please amend the claims as follows. The following Listing of Claims shall then supercede all prior listings of claims:

Listing of Claims:

1. (Currently Amended) An isolated nucleic acid encoding a lysophospholipid-specific human brain lysophospholipase enzyme protein molecule, comprising the nucleotide sequence of SEQ.ID.No. 1.
2. (Cancelled).
3. (Withdrawn) A recombinant lysophospholipid-specific human brain lysophospholipase enzyme protein molecule, comprising:
a single 25 kDa polypeptide having 230 amino acid residues; and
a catalytic activity site triad at S34-119, Asp-174 and His-208.
4. (Withdrawn) An amino acid residue sequence for a recombinant lysophospholipid-specific human brain lysophospholipase enzyme protein molecule, comprising:
amino acid residues from amino acid residue position 1 to amino acid residue position 230 in Figure 1.
5. (Withdrawn) A method for inhibiting catalytic activity of a recombinant lysophospholipid-specific human brain lysophospholipase enzyme protein molecule, comprising:
exposing the lysophospholipase enzyme protein molecule to a solution containing methyl arachidonyl fluorophosphates.

In re Application of:

Dennis et al.

Application No.: 09/493,601

Filed: January 28, 2000

Page 3

PATENT

Attorney Docket No.: ST-UCSD3130

(formerly 041673-0301)

6. (Withdrawn) The method for inhibiting catalytic activity according to claim 5, wherein the inhibiting resulting from the exposing is irreversible.
7. (Withdrawn) A method for treating patients with diseases caused by increased levels of lysophospholipids, comprising:
supplying a recombinant lysophospholipid-specific lysophospholipase enzyme to an enzyme deficient patient.
8. (Withdrawn) The method for treating patients according to claim 7, wherein the supplying transpires by infusion.
9. (Withdrawn) The method for treating patients according to claim 7, wherein the supplying transpires by gene augmentation therapy.
10. (Previously Presented) A recombinant expression vector containing the nucleic acid according to claim 1.
11. (Previously Presented) A host cell containing the recombinant expression vector of claim
12. (Previously Presented) A pharmaceutical composition comprising the nucleic acid of claim 1 and a pharmaceutically acceptable carrier.